Preclinical Pharmacokinetics and Bioavailability of VRDN-002, a Next-Generation Half-Life Extended Antagonist Antibody to the IGF-1 Receptor for Thyroid Eye Disease (TED)

Name: Viridian Therapeutics, Inc.
Address: 221 Crescent Street, Suite 103A, Waltham, Massachusetts, 02453, United States

Association for Research in Vision and Ophthalmology 2023 Annual Meeting | April 2023